Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

INmune Bio (INMB)

INmune Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:INMB
DateTimeSourceHeadlineSymbolCompany
16/05/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
16/05/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
16/05/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
16/05/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
16/05/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
16/05/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
09/05/202421:05GlobeNewswire Inc.INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateNASDAQ:INMBINmune Bio Inc
07/05/202413:00GlobeNewswire Inc.INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9NASDAQ:INMBINmune Bio Inc
30/04/202413:00GlobeNewswire Inc.INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsNASDAQ:INMBINmune Bio Inc
29/04/202413:00GlobeNewswire Inc.INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:INMBINmune Bio Inc
25/04/202414:00GlobeNewswire Inc.INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:INMBINmune Bio Inc
23/04/202413:00GlobeNewswire Inc.INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayNASDAQ:INMBINmune Bio Inc
22/04/202413:00GlobeNewswire Inc.INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingNASDAQ:INMBINmune Bio Inc
08/04/202413:00GlobeNewswire Inc.INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024NASDAQ:INMBINmune Bio Inc
28/03/202420:01GlobeNewswire Inc.INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateNASDAQ:INMBINmune Bio Inc
26/03/202420:01GlobeNewswire Inc.INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28NASDAQ:INMBINmune Bio Inc
13/03/202412:00GlobeNewswire Inc.INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene TherapyNASDAQ:INMBINmune Bio Inc
05/03/202413:00GlobeNewswire Inc.INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™NASDAQ:INMBINmune Bio Inc
12/02/202414:00GlobeNewswire Inc.INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:INMBINmune Bio Inc
06/02/202414:00GlobeNewswire Inc.INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024NASDAQ:INMBINmune Bio Inc
30/01/202413:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
30/01/202413:00GlobeNewswire Inc.INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease ProgramNASDAQ:INMBINmune Bio Inc
16/01/202413:30GlobeNewswire Inc.ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing TechnologyNASDAQ:INMBINmune Bio Inc
02/01/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
02/01/202413:00GlobeNewswire Inc.INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:INMBINmune Bio Inc
18/12/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
18/12/202321:05Edgar (US Regulatory)Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]NASDAQ:INMBINmune Bio Inc
18/12/202321:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
18/12/202321:01GlobeNewswire Inc.INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDANASDAQ:INMBINmune Bio Inc
29/11/202321:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
 Showing the most relevant articles for your search:NASDAQ:INMB